Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Voyager-V1 + ruxolitinib
- Development stage
- Unknown
- Lead developer
- Vyriad
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Voyager-V1 + ruxolitinib is an investigational combination therapy consisting of Voyager-V1 (VSV-hIFNbeta-NIS), an engineered oncolytic vesicular stomatitis virus (VSV), and ruxolitinib, a small molecule JAK1/JAK2 inhibitor. Developed by Vyriad in partnership with Mayo Clinic, Voyager-V1 is designed to selectively replicate in and destroy cancer cells while expressing human interferon-beta (IFNβ) to stimulate antitumor immunity and the sodium iodide symporter (NIS) to enable SPECT/PET-based tracking of viral spread. Ruxolitinib is co-administered to transiently inhibit the JAK/STAT pathway, thereby dampening innate antiviral interferon signaling and enhancing the replication, spread, and oncolytic efficacy of Voyager-V1 within the tumor microenvironment. The combination is being evaluated in Phase 1 clinical trials for the treatment of relapsed/refractory multiple myeloma, acute myeloid leukemia, T-cell lymphoma, and stage IV or recurrent endometrial cancer.
- Other names
- VSV-IFNβ-NIS + ruxolitinibVSV-hIFNbeta-NIS + ruxolitinibVSV-hIFNbeta-NIS + ruxolitinib phosphateVSV-hIFNβ-NIS + ruxolitinibVSV-hIFNβ-NIS + ruxolitinib phosphateVoyager-V1 + JakafiVoyager-V1 + JakaviVoyager-V1 + ruxolitinib phosphateVV1 + ruxolitinib
02
Targets
JAK1 (Janus kinase 1)JAK2 (Janus kinase 2)JAK3 (Janus kinase 3)TYK2 (Tyrosine kinase 2)IFNAR1 (Interferon alpha/beta receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)LDLR (Low-density lipoprotein receptor)NIS (Human sodium iodide symporter)
Beyond the preview
Go deeper on Voyager-V1 + ruxolitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Voyager-V1 + ruxolitinib.